NeoGenomics, Inc.
—- Market cap
- —
- Debt
- —
- Cash
- −$159.62M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NEO stock price vs WPC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WPC's multiple
Needs Annual EPS, WPC P/E.
Implied fair value · at NEO's multiple
Needs Annual EPS, NEO P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NeoGenomics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
W. P. Carey Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
NEO vs LH
QUEST DIAGNOSTICS INC
NEO vs DGX
OPKO HEALTH, INC.
NEO vs OPK
Guardant Health, Inc.
NEO vs GH
Natera, Inc.
NEO vs NTRA
EXACT SCIENCES CORP
NEO vs EXAS
ALEXANDRIA REAL ESTATE EQUITIES, INC.
NEO vs ARE
Brixmor Property Group Inc.
NEO vs BRX
KIMCO REALTY CORP
NEO vs KIM
REALTY INCOME CORP
NEO vs O
ESSENTIAL PROPERTIES REALTY TRUST, INC.
NEO vs EPRT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.